GATC Health Featured in The Dominion Post
June 18, 2026 — A recent article in The Dominion Post featured GATC Health’s Chief Business Officer, Tyrone Lam, and Senior Scientist and Discovery Lead, Dr. Alexa Martin.
The article titled “GATC Health’s Morgantown lab uses AI to develop drug to treat opioid use disorder” highlighted the development of GATC-1021 at the Morgantown laboratory, the recently published preclinical findings, and the role of the Operon® platform in identifying the candidate. It further explored the potential for a novel, non-hallucinogenic approach to treating OUD, efforts to address the stigma surrounding OUD, and the significance of advancing this research in West Virginia.
Read the full article here: GATC Health’s Morgantown lab uses AI to develop drug to treat opioid use disorder.
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
GATC Health Featured on Citeline’s In Vivo Podcast: A “FICO Score” for Drug Development
June 17, 2026 — In the episode, titled “GATC Health’s Derisq AI, A FICO Score For Drug Development,” GATC Health Chief Business Officer Ty…
Read more
GATC Health Strengthens Commercial and Pharma Strategy Leadership to Accelerate Market Adoption of Its AI Platform
IRVINE, CA — Feb. 26, 2026 — GATC Health, a leading tech-bio company leveraging AI to transform drug discovery and development, is pro…
Read more
GATC Health Receives Concentrated Media Visibility Across AI, Capital Markets and Regulatory Policy Conversations
Recent coverage in BioSpace and GEN highlights GATC’s growing relevance in industry discussions spanning AI adoption, biotech financing, de…
Read more